Boehringer Ingelheim’s and Eli Lilly’s Jardiance Granted Fast-Track Status for Heart Attacks

The FDA has granted a Fast-Track designation to Boehringer Ingelheim’s and Eli Lilly’s Jardiance (empagliflozin) for the prevention of hospitalization for heart failure and to reduce the risk of mortality in patients who have had a heart attack.

Jardiance is currently being tested in a phase 3 clinical trial to evaluate its effect on all-cause mortality and hospitalization for heart failure in adults with and without type 2 diabetes who have had a heart attack and have no history of chronic failure. Results of the late-stage trial are expected by 2023.

Jardiance is currently approved for lowering blood sugar in adults with type 2 diabetes and for reducing the risk of cardiovascular death in patients with type 2 diabetes and known cardiovascular disease.